Conversation with The Cancer Letter Roy Herbst: I hope Pragmatica-Lung will become the norm December 02, 2022Vol.48 No.43By Jacquelyn Cobb and Paul Goldberg
Conversation with The Cancer Letter Ellen Sigal: Pragmatica-Lung may be a model for other trials that are unnecessarily complex December 02, 2022Vol.48 No.43By Matthew Bin Han Ong
In Brief Martha Donoghue named FDA OCE associate director for pediatric oncology and rare cancers December 02, 2022Vol.48 No.43
Drugs & Targets FDA approves Rezlidhia for R/R AML with a susceptible IDH1 mutation December 02, 2022Vol.48 No.43
Drugs & Targets Genentech voluntarily withdraws U.S. indication of Tecentriq for types of bladder cancer December 02, 2022Vol.48 No.43
Drugs & Targets FDA grants accelerated approval to Elahere for platinum-resistant ovarian cancer November 18, 2022Vol.48 No.42
Drugs & Targets FDA approves Imjudo + Imfinzi and platinum-based chemo for metastatic NSCLC November 11, 2022Vol.48 No.41
Drugs & Targets FDA approves Adcetris + chemo for pediatric classical Hodgkin lymphoma November 11, 2022Vol.48 No.41
Regulatory News ODAC considers the first application based wholly on RWE methodology—and nixes it unanimously November 04, 2022Vol.48 No.40By Paul Goldberg
